ASCRS Guidelines: FAP, AP, and Rectal Polyposis Management
Welcome to Colorectal Surgery Review. In this episode, we deliver an evidence-based clinical breakdown of the 2023 American Society of Colon and Rectal Surgeons (ASCRS) Clinical Practice Guidelines for the Management of Familial Adenomatous Polyposis (FAP) and associated polyposis syndromes. Designed for practicing colon and rectal surgeons, surgical oncologists, and senior trainees preparing for board certification, this deep dive translates complex genetic data, anatomical considerations, and guideline algorithms into actionable surgical strategies. Key Clinical Topics Covered: Genetics & Pathophysiology: How APC gene mutations drive classical FAP, the concept of somatic mosaicism in attenuated FAP (AFAP), and the profound clinical implications of MUTYH-associated polyposis (MAP). We also discuss why 20-50% of patients presenting with an attenuated phenotype lack an identifiable pathogenic variant (the "genetic void"). Preoperative Staging & Extracolonic Disease: The critical shift to baseline upper endoscopy starting at age 20-25 to monitor for duodenal adenocarcinomas, which represent the leading cause of non-colorectal mortality in FAP. Surgical Timing & Prophylactic Colectomy: Why prophylactic surgery in classical FAP is typically delayed until the late teens or early 20s, balancing the 100% lifetime cancer risk against the psychosocial and functional burden of early intervention. The Surgical Triad: Detailed algorithmic decision-making between: Chemoprevention & Medical Management: The current (and often debated) role of NSAIDs (Sulindac) and COX-2 inhibitors (Celecoxib) in delaying polyp progression or managing retained rectal stump polyposis. Desmoid Tumors: The second leading cause of mortality in FAP patients. We explore why intra-abdominal surgical trauma often precipitates their aggressive growth and the modern shift toward non-operative, medical management of these challenging fibromatous lesions.